Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · IEX Real-Time Price · USD
10.25
-0.17 (-1.63%)
At close: Jul 19, 2024, 4:00 PM
10.26
+0.01 (0.10%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Dynavax Technologies Employees
Dynavax Technologies had 408 employees as of December 31, 2023. The number of employees increased by 57 or 16.24% compared to the previous year.
Employees
408
Change (1Y)
57
Growth (1Y)
16.24%
Revenue / Employee
$578,797
Profits / Employee
$22,603
Market Cap
1.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 408 | 57 | 16.24% |
Dec 31, 2022 | 351 | 40 | 12.86% |
Dec 31, 2021 | 311 | 66 | 26.94% |
Dec 31, 2020 | 245 | 14 | 6.06% |
Dec 31, 2019 | 231 | -18 | -7.23% |
Dec 31, 2018 | 249 | 79 | 46.47% |
Dec 31, 2017 | 170 | -81 | -32.27% |
Dec 31, 2016 | 251 | 17 | 7.26% |
Dec 31, 2015 | 234 | 37 | 18.78% |
Dec 31, 2014 | 197 | 46 | 30.46% |
Dec 31, 2013 | 151 | -16 | -9.58% |
Dec 31, 2012 | 167 | 17 | 11.33% |
Dec 31, 2011 | 150 | 22 | 17.19% |
Dec 31, 2010 | 128 | -2 | -1.54% |
Dec 31, 2009 | 130 | -25 | -16.13% |
Dec 31, 2008 | 155 | -18 | -10.40% |
Dec 31, 2007 | 173 | 20 | 13.07% |
Dec 31, 2006 | 153 | 76 | 98.70% |
Dec 31, 2005 | 77 | 6 | 8.45% |
Dec 31, 2004 | 71 | 27 | 61.36% |
Dec 31, 2003 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Phreesia | 1,438 |
ANI Pharmaceuticals | 642 |
Vir Biotechnology | 587 |
Arcus Biosciences | 577 |
Nurix Therapeutics | 284 |
Day One Biopharmaceuticals | 155 |
Disc Medicine | 74 |
DVAX News
- 24 days ago - Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program - PRNewsWire
- 7 weeks ago - Dynavax to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine - Reuters
- 2 months ago - Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S. - PRNewsWire
- 2 months ago - Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates - PRNewsWire
- 3 months ago - Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - PRNewsWire
- 5 months ago - Dynavax to Present at TD Cowen's 44th Annual Health Care Conference - PRNewsWire
- 5 months ago - Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance - PRNewsWire